Introduction
Gastric cancer is the third leading cause of cancer death worldwide [1] . Nearly 50% of patients with locally advanced-stage gastric cancer relapse after gastrectomy, resulting in an unfavourable long-term prognosis [2] . The survival of these patients has been demonstrated to be markedly improved upon introduction of postoperative adjuvant chemotherapy with S-1 monotherapy [3] . However, a number of patients develop early recurrence after completion of adjuvant therapy with S-1.
On the other hand, combination therapies with fluoropyrimidines and platinum have been recognised as standard regimens for the first-line treatment of advanced gastric cancer (AGC) [4] . In addition, EOX (epirubicin, oxaliplatin and capecitabine) has also become a standard regimen in Europe [5] , and DCF (cisplatin [CDDP], 5fluorouracil and docetaxel) has been developed in the US, although its application is limited because of high toxicity [6] . In contrast, when this study started, S-1 monotherapy was widely used as a standard regimen in Japan [7] . Although the result of the JCOG 9912 trial showed that S-1 monotherapy was tentatively recognised as a standard treatment, the result of the SPIRTS trial proved the superiority of S-1 plus CDDP combination therapy over S-1 monotherapy [8] . However, the S-1 monotherapy regimen showed good overall survival (OS) in both trials (11.4 and 11 .0 months, respectively), and owing to its modest toxicity and the fact that intensive hydration is not required, S-1 monotherapy remains an option for frail or unfit patients in Japan.
It is common practice to offer further chemotherapy for patients with AGC after failure of first-line chemotherapies [9] . However, currently, no established second-line chemotherapy (SLC) regimen is available for AGC patients. When we designed this trial, irinotecan (CPT-11) plus CDDP combination therapy or CPT-11 monotherapy were commonly used to treat AGC in the second-line setting in Asia [10] [11] [12] [13] . In a previous phase II study using CPT-11 monotherapy as SLC, CPT-11 was found to frequently cause diarrhoea and febrile neutropenia [10] ; therefore, CPT-11/CDDP combination therapy was developed to reduce CPT-11-associated diarrhoea and febrile neutropenia by decreasing the dose of CPT-11 [12, 13] . Moreover, a phase I/II study of bi-weekly CPT-11/CDDP combination therapy showed promising efficacy and a manageable toxicity profile [13] .
However, the effects of platinum-based therapies in the second-line setting for AGC patients initially treated by S-1 monotherapy have not yet been examined; therefore, this trial was designed to compare the effects of combination therapy with CPT-11 and CDDP to CPT-11 monotherapy in patients who showed progression after at least one cycle of S-1 monotherapy for advanced cancer or recurrence within 6 months after completion of adjuvant therapy with S-1.
Patients and methods

Patients
Patients aged P20 years were eligible for inclusion in this multicentre, open-label, randomised phase III gastric cancer chemotherapy trial in a second line setting. Patients with histologically confirmed AGC that were refractory to the first-line S-1 monotherapy. Tumour progression after at least one cycle of S-1 monotherapy for an advanced cancer, or recurrence within 6 months after the completion of adjuvant therapy with S-1 were considered eligible for the study. Patients who have discontinued S-1 monotherapy due to the adverse events were excluded from this study. Adequate organ function and an Eastern Cooperative Oncology Group performance status (PS) of 0 or 1 were confirmed by respective laboratory tests (white blood cell count P4000/mm 3 and 612,000/mm 3 , neutrophil count P2000/mm 3 , platelet count P100,000/mm 3 , haemoglobin level P8.0 g/dL, aspartate aminotransferase and alanine aminotransferase (ALT) levels 6100 IU/L, total bilirubin level 61.50 mg/dL, and creatinine level 61.20 mg/dL) and physical examinations. Exclusion criteria included a PS P2, history of anti-tumour therapy (except for S-1 monotherapy and surgery), additional malignancies or significant comorbidities. A treatment-free interval of at least 2 weeks after S-1 monotherapy and 4 weeks after surgery was required to be eligible for the trial.
The trial was conducted in accordance with the Declaration of Helsinki and registered with UMIN-CTR, UMIN 000002571. All patients provided written informed consent after having been informed about the purpose and investigational nature of the study. The institutional review boards or ethics committees of all participating centres reviewed and approved the protocol.
The participating investigators were instructed to send an eligibility criteria report to the data centre, operated by the non-profit organisation Epidemiological & Clinical Research Information Network (ECRIN). Eligible patients were registered and subsequently Randomised using a centralised dynamic randomisation method with the following balancing factors: PS (0/1); disease type (patients with progressive disease/patients with recurrence); measurable disease according to the criteria set by Response Evaluation Criteria in Solid Tumours (RECIST 1.0) (yes/no), and institution. The accrual started in July 2007 and was continued for 4 years.
Projected treatment
Patients in the CPT-11/CDDP arm received intravenous CPT-11 (60 mg/m 2 ) and CDDP (30 mg/m 2 ) on day 1 and every 2 weeks thereafter. Patients in the CPT-11 arm received intravenous CPT-11 (150 mg/m 2 ) on day 1 and every 2 weeks thereafter. The pre-specified regimens were discontinued if any of the following was observed: (i) disease progression or occurrence of new disease; (ii) grade 4 non-haematological toxicities evaluated according to the Common Terminology Criteria for Adverse Events, version 3.0; (iii) adverse events causing patients to refuse treatment or causing a clinician to discontinue treatment; (iv) increase in the levels of tumour markers in two or more consecutive measurements; or (v) symptomatic progression.
Follow-up
Disease progression and occurrence of new disease were examined using chest radiography and computed tomography (CT). These were performed at baseline and at least every 4-6 weeks during treatment, according to the RECIST version 1.0. Blood tests and symptom checks were performed at least every 2 weeks during treatment.
Study design and statistical methods
The primary end-point of this study was overall survival (OS), which was defined as the time from the date of random assignment to the date of death as a result of any cause. OS, progression-free survival (PFS) and time to treatment failure (TTF) curves were constructed as time-to-event plots using the Kaplan-Meier method. Time-to-event curves were compared using log-rank tests and hazard ratio (HR) estimated by Cox regression models. The efficacy analysis was performed using intent-to-treat populations, wherein all randomly assigned patients were included. It was assumed that the OS would be 5 months in the CPT-11 arm and 8 months in the CPT-11/CDDP arm. The power of the test was estimated as 80% with a two-sided a value of 0.05, which indicated a sample size of 80 subjects in each arm (a total of 160 subjects). When ineligible patients or dropouts were included, the initial target sample size was estimated to be 200. All clinical data were held centrally at the ECRIN data centre and analysed using SAS for Windows version 9.3 (SAS Institute Inc., Cary, NC, United States of America (USA)).
Results
Patient characteristics
In total, 168 patients were enrolled from 30 institutes in Japan between July 2007 and December 2011. This study was ended when the pre-determined number of enrolled subjects was obtained. The numbers of patients in the CPT-11/CDDP and CPT-11 arm were 84 and 84, respectively. Three cases in the CPT-11/CDDP arm and two cases in the CPT-11 arm refused to undergo treatment before the start of the assigned treatment.
Therefore, 82 and 81 patients in the CPT-11/CDDP and CPT-11 arm, respectively, were considered eligible for evaluation ( Fig. 1) . The initial patient characteristics between the two arms were well matched (Table 1) , and the median follow-up duration was 59.0 months.
Survival
A total of 69 patients (82%) in the CPT-11/CDDP arm and 70 patients (83%) in the CPT-11 arm had died at the end of the study. In the intention-to-treat survival analysis, the median OS was 13.9 (95% confidence interval [CI]: 10.8-17.6) months in the CPT-11/CDDP arm and 12.7 (95% CI: 10.3-17.2) months in the CPT-11 arm. Thus, CPT-11/CDDP combination therapy did not significantly reduce the risk of death compared with CPT-11 monotherapy (hazard ratio [HR]: 0.834; 95% CI: 0.596-1.167, P = 0.288; Fig. 2A) . Similarly, no difference was observed in the median PFS (4.6 months versus 4.1 months, respectively; HR: 0.860; 95% CI: 0.610-1.203, P = 0.376; Fig. 2B ) and the median TTF (3.3 months versus 3.5 months; HR: 1.009; 95% CI: 0.740-1.375, P = 0.956) between the CPT-11/CDDP and CPT-11 arms.
Exploratory subgroup analysis revealed that CPT-11/ CDDP combination therapy was associated with significantly better OS in intestinal-type gastric adenocarcinomas compared to CPT-11 monotherapy (median OS: 15.8 months versus 14.0 months; HR: 0.569; 95% CI: 0.352-0.918, P = 0.019; Fig. 3 ). CPT-11/CDDP combination therapy was not associated with any other factors, including age, gender, disease status, PS, primary site, histology, peritoneal metastasis, liver metastasis, target lesion and number of metastases.
Response rates
Of the 82 patients treated with CPT-11/CDDP combination therapy (65 patients had measurable disease), three achieved complete response (CR), eight achieved Table 2 ). No significant difference was observed between the arms (P = 0.812).
Toxicity
All patients could be assessed for haematological and non-haematological toxicities. Proportions of patients who had presented any types of toxicity are shown in Table 3 . Compared to the CPT-11 arm, the CPT-11/ CDDP arm showed significantly higher grade 3-4 toxicities, regarding anaemia (16% versus 4%) and lactate dehydrogenase level (5% versus 0%). With regard to the incidence of any grade of adverse events, leucopenia, thrombocytopenia and increase of serum creatinine were more frequently observed in the CPT-11/CDDP arm, whereas diarrhoea, constipation and mucositis were more commonly noted in the CPT-11 arm. There were no deaths resulting from toxicities.
Compliance
The median number of courses was five (range, 1-31) in the CPT-11/CDDP arm and 6 (range, 1-39) in the CPT-11 arm, respectively. Treatment delays were more frequently observed in the CPT-11/CDDP arm (61% versus 44%; P = 0.035). The most common reasons for discontinuation in the CPT-11/CDDP and CPT-11 arms were disease progression (59% and 74%, respectively) and adverse events (28% and 11%, respectively). However, this was not statistically significant. A greater number of patients in the CPT-11/CDDP arm were unable to start new cycles within 4 weeks from the last administration because of toxicities, compared to the CPT-11 arm.
Post-protocol therapy
Post-protocol therapy was administered in 71% (58/ 81) and 68% (55/81) of patients in the CPT-11/CDDP and CPT-11 arms, respectively. We could not find any significant difference in the regimens selected as postprotocol therapy between the arms. Among the 55 patients in the CPT-11 arm, 46 patients did not receive CDDP-based therapy throughout chemotherapy from first-line to salvage therapy.
Discussion
Our study did not show that CPT-11/CDDP combination therapy was superior to CPT-11 monotherapy in platinum-naïve patients with progressive AGC previously treated with S-1 monotherapy (HR: 0.834; 95% CI: 0.596-1.167; P = 0.288). The hypothesised survivals in the statistical calculation of the protocol (estimated median survival time: 8 versus 5 months) were much shorter than those obtained in the trial (observed median survival 13.9 versus 12.7 months). These differences may have influenced the power of this trial, making it underpowered to observe real differences in overall survival. If it was assumed that the OS would be 12.7 months in the CPT-11 arm, 1040 patients would be needed to detect a survival benefit of 3 months in OS in the CPT/CDDP arm with a power of 80%. The favourable long-term survivals observed in this trial may be due to the good prognostic characteristics of the patients, as only patients with PS 0-1 were considered. Moreover, the median number of metastatic sites was only 1, and only 21% of patients had 2 or more metastatic sites. As a result, a high proportion of the patients (69%) who progressed after the allocated treatments had received further treatment in this study. Further, patients in this trial did not receive platinumbased first-line chemotherapy, which permitted a longer duration of SLC, and the enrolment rate of recurrent cases within 6 months after S-1 adjuvant chemotherapy was high (58%, 97/168).
While the present study was ongoing, three trials demonstrated a prolongation of survival with SLC (CPT-11 or docetaxel monotherapy) over best supportive care [14] [15] [16] , and a meta-analysis of these trials supported the efficacy of SLC in the treatment of AGC [17] . In this meta-analysis, a significant reduction in the risk of death (HR: 0.64, P < 0.0001) was observed with salvage chemotherapy (HR: 0.55 and 0.71 for CPT-11 and docetaxel, respectively).
The role of molecular targeted agents in second-line therapy has gained interest. Recent trials reported that ramucirumab monotherapy improved OS compared to best supported care [18] , and its combination with weekly paclitaxel improved OS and PFS over weekly paclitaxel alone [19] . Furthermore, a recent meta-analysis of chemotherapy or targeted therapy [20] reported that a benefit of chemotherapy was found for patients with good PS, while targeted agents showed some efficacy for patients with PS 1 or more, indicating that symptomatic disease should not be immediately excluded for further lines of therapy.
Recently, Higuchi et al. reported in their randomised trial (n = 130), employing the same regimens as in this trial, that biweekly CPT-11 plus CDDP significantly prolonged PFS (HR: 0.68) compared with CPT-11 alone, but that it did not demonstrate a survival benefit (HR: 1.00) in patients with metastatic or recurrent gastric cancer that progressed after S-1-based first-line chemotherapy. In their study, approximately 30% and 60% of patients received S-1 monotherapy and combination of S-1 and platinum-based therapy, respectively [21] . Thus, taken together with the results of the present study, the addition of platinum to CPT-11 as secondline treatment may not have a survival benefit, regardless of pretreatment with platinum.
Interestingly, our exploratory subgroup analysis revealed that CPT-11/CDDP combination therapy was significantly more effective for intestinal-type gastric cancer than CPT-11 monotherapy, and similar results are found in the literature, indicating that CPT-11/ CDDP combination therapy may be particularly effective in intestinal-type as compared with diffuse-type gastric cancer [4, 22] . On the other hand, the efficacies of the regimens did not differ between recurrent cases after S-1 adjuvant and advanced cases showing progression after S-1 treatment, indicating that the disease status may not affect the treatment effect.
Our trial has several limitations. The number of eligible patients was small and the prognoses of these patients were better than expected. Therefore, a possibility of type two error cannot be denied. Further, application of the present results may be limited, as combination therapies containing platinum are currently the standard first-line treatment. Lastly, with the exception of histology type, we could not explore the factors predictive of a benefit of addition of platinum to platinum-naïve patients. In conclusion, our study did not show a significant difference in OS between CPT-11/CDDP combination therapy and CPT-11 monotherapy in patients with progressive AGC previously treated with S-1 monotherapy. However, in the subset analysis, we found that CPT-11/ CDDP combination therapy was associated with a better OS in intestinal-type AGC.
